A detailed history of Bvf Inc transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Bvf Inc holds 3,853,818 shares of OVID stock, worth $4.2 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
3,853,818
Previous 3,853,818 -0.0%
Holding current value
$4.2 Million
Previous $2.97 Million 53.25%
% of portfolio
0.14%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.72 - $4.04 $8.15 Million - $12.1 Million
-2,997,233 Reduced 43.75%
3,853,818 $11.8 Million
Q1 2022

May 16, 2022

BUY
$2.65 - $3.49 $583,000 - $767,800
220,000 Added 3.32%
6,851,051 $21.5 Million
Q2 2021

Aug 16, 2021

BUY
$3.3 - $4.49 $704,550 - $958,615
213,500 Added 3.33%
6,631,051 $25.9 Million
Q1 2021

May 17, 2021

BUY
$2.42 - $4.47 $4.59 Million - $8.47 Million
1,895,500 Added 41.92%
6,417,551 $25.8 Million
Q4 2020

Feb 12, 2021

BUY
$2.28 - $6.84 $2.05 Million - $6.16 Million
900,000 Added 24.85%
4,522,051 $10.4 Million
Q3 2020

Nov 13, 2020

BUY
$5.39 - $8.24 $6.63 Million - $10.1 Million
1,229,900 Added 51.41%
3,622,051 $20.8 Million
Q2 2020

Aug 14, 2020

BUY
$2.67 - $7.91 $2.95 Million - $8.75 Million
1,106,147 Added 86.01%
2,392,151 $17.6 Million
Q1 2020

May 15, 2020

BUY
$2.03 - $4.35 $1.12 Million - $2.4 Million
551,703 Added 75.13%
1,286,004 $3.83 Million
Q4 2019

Feb 14, 2020

SELL
$2.08 - $5.06 $3.3 Million - $8.03 Million
-1,586,935 Reduced 68.37%
734,301 $3.05 Million
Q3 2019

Nov 14, 2019

SELL
$1.76 - $3.51 $2.22 Million - $4.43 Million
-1,262,000 Reduced 35.22%
2,321,236 $7.52 Million
Q2 2019

Aug 14, 2019

BUY
$1.59 - $2.14 $461,475 - $621,105
290,236 Added 8.81%
3,583,236 $6.63 Million
Q1 2019

May 15, 2019

BUY
$1.77 - $3.56 $5.83 Million - $11.7 Million
3,293,000 New
3,293,000 $5.83 Million

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $76.8M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Bvf Inc Portfolio

Follow Bvf Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.